Tag: non-alcoholic steatohepatitis (nash) market trends

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Future Market Size Estimation For The Non-Alcoholic Steatohepatitis (NASH) Market Covering 2025–2034?

The market size for non-alcoholic steatohepatitis (NASH) has experienced substantial expansion in recent years. Projections indicate it will advance from $4.5 billion in 2024 to $6.06 billion by 2025, propelled by a compound annual growth rate (CAGR) of 34.7%. This historical market expansion is primarily attributable to factors such as the increasing prevalence of NASH, the global obesity epidemic, rising awareness and diagnostic efforts, evolving lifestyle and dietary patterns, and improvements in healthcare infrastructure.

The non-alcoholic steatohepatitis (NASH) market size is anticipated to undergo significant expansion over the next few years. It is projected to reach $18.55 billion by 2029, growing at a compound annual growth rate (CAGR) of 32.3%. This growth during the forecast period can be attributed to advancements in NASH drug development, increasing NASH screening initiatives, rising healthcare expenditure, collaborative research efforts, and government support and regulations. Prominent trends expected in this period include a focus on lifestyle interventions and patient education, enhanced collaboration in clinical research, regulatory improvements and pathway designations, and the integration of artificial intelligence in diagnosis and monitoring.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8805&type=smp

Which Major Market Drivers Are Shaping The Future Of The Non-Alcoholic Steatohepatitis (NASH) Market?

The increasing prevalence of obesity is fueling demand for the non-alcoholic steatohepatitis (NASH) market moving forward. Obesity is defined as an abnormal or excessive accumulation of fat that poses a health risk, or body weight exceeding what is considered healthy or typical for an individual of a specific height. As non-alcoholic fatty liver disease has become more common due to the rising obesity pandemic, NASH is anticipated to become the most widespread cause of severe liver disease in the coming decades, thereby driving the need for NASH treatments and related drugs. For instance, in March 2024, the World Health Organization (WHO), a UK-based international public health organization, reported that in 2022, approximately 2.5 billion adults aged 18 and older were categorized as overweight, with 890 million of them experiencing obesity. Consequently, the increase in obesity cases will propel the growth of the non-alcoholic steatohepatitis (NASH) market.

What Are The Major Segment Categories Driving The Non-Alcoholic Steatohepatitis (NASH) Market Growth?

The non-alcoholic steatohepatitis (nash) market covered in this report is segmented –

1) By Type: Solid, Liquid

2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products

3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity

4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider

5) By Application: Oral, Parenteral

Subsegments:

1) By Solid: Tablets, Capsules, Other Solid Dosage Forms

2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms

Which Key Trends Are Expected To Influence The Non-Alcoholic Steatohepatitis (NASH) Market In The Coming Years?

Major companies in the non-alcoholic steatohepatitis (NASH) market are developing thyroid hormone receptor-beta (THR-beta) agonists with the goal of improving liver metabolism, decreasing liver fat accumulation, and enhancing liver function. Thyroid hormone receptor-beta (THR-beta) agonists are compounds that specifically activate the thyroid hormone receptor-beta subtype, a vital receptor involved in regulating metabolism, growth, and development. For instance, in March 2024, the Food and Drug Administration, a US-based regulatory body, approved Rezdiffra (resmetirom), a thyroid hormone receptor-beta agonist, as the first treatment for adults experiencing noncirrhotic NASH with moderate to advanced liver scarring (fibrosis). By selectively engaging the THR-beta receptor, Rezdiffra aids in regulating lipid metabolism, which leads to a reduction in intrahepatic triglycerides and overall liver fat accumulation.

Who Are The Major Companies Operating In The Non-Alcoholic Steatohepatitis (NASH) Market?

Major companies operating in the non-alcoholic steatohepatitis (NASH) market include NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-nash-global-market-report

How Does The Non-Alcoholic Steatohepatitis (NASH) Market Perform Across Key Geographic Regions?

North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Non-Alcoholic Steatohepatitis (NASH) Market Report:

https://www.thebusinessresearchcompany.com/customise?id=8805&type=smp

Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis (NASH) Market 2025, By The Business Research Company

Alcoholic Beverages Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/alcoholic-beverages-global-market-report

Grain Products Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/grain-products-global-market-report

Grain Farming Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/grain-farming-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Future Market Size Estimation For The Non-Alcoholic Steatohepatitis (NASH) Market Covering 2025–2034?

The market size for non-alcoholic steatohepatitis (NASH) has experienced substantial expansion in recent years. Projections indicate it will advance from $4.5 billion in 2024 to $6.06 billion by 2025, propelled by a compound annual growth rate (CAGR) of 34.7%. This historical market expansion is primarily attributable to factors such as the increasing prevalence of NASH, the global obesity epidemic, rising awareness and diagnostic efforts, evolving lifestyle and dietary patterns, and improvements in healthcare infrastructure.

The non-alcoholic steatohepatitis (NASH) market size is anticipated to undergo significant expansion over the next few years. It is projected to reach $18.55 billion by 2029, growing at a compound annual growth rate (CAGR) of 32.3%. This growth during the forecast period can be attributed to advancements in NASH drug development, increasing NASH screening initiatives, rising healthcare expenditure, collaborative research efforts, and government support and regulations. Prominent trends expected in this period include a focus on lifestyle interventions and patient education, enhanced collaboration in clinical research, regulatory improvements and pathway designations, and the integration of artificial intelligence in diagnosis and monitoring.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8805&type=smp

Which Major Market Drivers Are Shaping The Future Of The Non-Alcoholic Steatohepatitis (NASH) Market?

The increasing prevalence of obesity is fueling demand for the non-alcoholic steatohepatitis (NASH) market moving forward. Obesity is defined as an abnormal or excessive accumulation of fat that poses a health risk, or body weight exceeding what is considered healthy or typical for an individual of a specific height. As non-alcoholic fatty liver disease has become more common due to the rising obesity pandemic, NASH is anticipated to become the most widespread cause of severe liver disease in the coming decades, thereby driving the need for NASH treatments and related drugs. For instance, in March 2024, the World Health Organization (WHO), a UK-based international public health organization, reported that in 2022, approximately 2.5 billion adults aged 18 and older were categorized as overweight, with 890 million of them experiencing obesity. Consequently, the increase in obesity cases will propel the growth of the non-alcoholic steatohepatitis (NASH) market.

What Are The Major Segment Categories Driving The Non-Alcoholic Steatohepatitis (NASH) Market Growth?

The non-alcoholic steatohepatitis (nash) market covered in this report is segmented –

1) By Type: Solid, Liquid

2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products

3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity

4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider

5) By Application: Oral, Parenteral

Subsegments:

1) By Solid: Tablets, Capsules, Other Solid Dosage Forms

2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms

Which Key Trends Are Expected To Influence The Non-Alcoholic Steatohepatitis (NASH) Market In The Coming Years?

Major companies in the non-alcoholic steatohepatitis (NASH) market are developing thyroid hormone receptor-beta (THR-beta) agonists with the goal of improving liver metabolism, decreasing liver fat accumulation, and enhancing liver function. Thyroid hormone receptor-beta (THR-beta) agonists are compounds that specifically activate the thyroid hormone receptor-beta subtype, a vital receptor involved in regulating metabolism, growth, and development. For instance, in March 2024, the Food and Drug Administration, a US-based regulatory body, approved Rezdiffra (resmetirom), a thyroid hormone receptor-beta agonist, as the first treatment for adults experiencing noncirrhotic NASH with moderate to advanced liver scarring (fibrosis). By selectively engaging the THR-beta receptor, Rezdiffra aids in regulating lipid metabolism, which leads to a reduction in intrahepatic triglycerides and overall liver fat accumulation.

Who Are The Major Companies Operating In The Non-Alcoholic Steatohepatitis (NASH) Market?

Major companies operating in the non-alcoholic steatohepatitis (NASH) market include NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-nash-global-market-report

How Does The Non-Alcoholic Steatohepatitis (NASH) Market Perform Across Key Geographic Regions?

North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Non-Alcoholic Steatohepatitis (NASH) Market Report:

https://www.thebusinessresearchcompany.com/customise?id=8805&type=smp

Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis (NASH) Market 2025, By The Business Research Company

Alcoholic Beverages Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/alcoholic-beverages-global-market-report

Grain Products Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/grain-products-global-market-report

Grain Farming Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/grain-farming-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Industry Valuation for the Non-Alcoholic Steatohepatitis (NASH) Sector?

The market size for non-alcoholic steatohepatitis (NASH) has witnessed remarkable growth in recent years. This market is set to expand from $4.5 billion in 2024 to $6.06 billion in 2025, with a compound annual growth rate (CAGR) of 34.7%. Factors such as an escalating prevalence of NASH, the obesity crisis, increasing awareness and diagnosis, transformation in lifestyle and food habits, and progression of healthcare infrastructure have contributed to the growth during the historic period.

In the upcoming years, the market size of non-alcoholic steatohepatitis (NASH) is predicted to experience significant growth, reaching “$18.55 billion in 2029 with a compound annual growth rate (CAGR) of 32.3%“. The expected growth in the forecasting period is largely due to factors such as advancements in NASH drug development, heightened initiatives for NASH screening, growing healthcare expenditure, joint research efforts, as well as governmental support and regulations. In the forecast period, the major trends that will affect the market include an emphasis on lifestyle modifications and patient education, an increased collaboration in clinical studies, advancements in regulations and pathway designations, and the implementation of artificial intelligence in diagnosis and monitoring.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8805&type=smp

What Forces Are Driving The Growth Of The Non-Alcoholic Steatohepatitis (NASH) Market?

The surge in obesity prevalence is fuelling a considerable demand for the non-alcoholic steatohepatitis (NASH) market. Obesity involves abnormal or excessive fat accumulation that carries health risks, including a body weight exceeding the healthy or normal limit for an individual’s height. The escalating obesity crisis is leading to a higher incidence of non-alcoholic fatty liver disease, which in turn might make NASH the leading cause of serious liver disease in the coming years. This trend underpins the growing need for NASH treatment and related medications. For example, the World Health Organization (WHO), a UK-based global public health body, stated in March 2024 that nearly 2.5 billion adults aged 18 and above were overweight in 2022, with around 890 million of them suffering from obesity. Thus, the increasing obesity rates are anticipated to propel the growth of the non-alcoholic steatohepatitis (NASH) market.

The non-alcoholic steatohepatitis (nash) market covered in this report is segmented –

1) By Type: Solid, Liquid

2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products

3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity

4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider

5) By Application: Oral, Parenteral

Subsegments:

1) By Solid: Tablets, Capsules, Other Solid Dosage Forms

2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms

Which Trends Are Redefining The Future Landscape Of The Non-Alcoholic Steatohepatitis (NASH) Industry?

Leading corporations in the non-alcoholic steatohepatitis (NASH) market are concentrating on the development of thyroid hormone receptor-beta (THR-beta) agonists. These agonists are designed to improve liver metabolism, decrease liver fat buildup, and enhance liver function. The THR-beta agonists work by selectively triggering the thyroid hormone receptor-beta subtype, a critical receptor controlling metabolism, growth, and development. For instance, in March 2024, the US-based regulatory body, the Food and Drug Administration, sanctioned the first treatment for adults with noncirrhotic NASH with medium to severe liver scarring (fibrosis), Rezdiffra (resmetirom), a THR-beta agonist. Rezdiffra functions by selectively activating the THR-beta receptor, which helps manage lipid metabolism, resulting in a decrease in intrahepatic triglycerides and liver fat buildup.

Which Companies Currently Dominate The Competitive Landscape In The Non-Alcoholic Steatohepatitis (NASH) Industry?

Major companies operating in the non-alcoholic steatohepatitis (NASH) market include NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens.

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-nash-global-market-report

Which Geographic Regions Are Driving Demand In The Non-Alcoholic Steatohepatitis (NASH) Market?

North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8805&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Projected Market Size and Growth Rates for the Non-Alcoholic Steatohepatitis (NASH) Market From 2025 To 2029?

The market size for non-alcoholic steatohepatitis (NASH) has seen a substantial surge in growth in the past few years. Its value is projected to increase from $4.5 billion in 2024 to $6.06 billion in 2025, showcasing a compound annual growth rate (CAGR) of 34.7%. The significant growth experienced during the historical period can be ascribed to factors such as the increasing cases of NASH, escalating obesity crisis, heightened awareness and detection rates, changes in lifestyle and food habits, and advancements in healthcare infrastructure.

Expectations for the non-alcoholic steatohepatitis (NASH) market show significant expansion in the upcoming years. Notably, it is projected to reach a market size of $18.55 billion by 2029, yielding a compound annual growth rate (CAGR) of 32.3%. This considerable growth can be credited to several factors, including advancements in NASH medication development, the rise in NASH screening initiatives, an increase in healthcare spending, combined research initiatives, and government regulatory support. Key tendencies expected during the forecast period comprise focusing on lifestyle modifications and patient education, fostering collaboration in clinical trials, regulatory progress and pathway designations, as well as the incorporation of artificial intelligence in diagnosis and supervision.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8805&type=smp

What Are the Core Market Drivers Propelling Growth in the Non-Alcoholic Steatohepatitis (NASH) Industry?

The escalating prevalence of obesity is fuelling the necessity for the non-alcoholic steatohepatitis (NASH) market. Obesity, characterized by abnormal or excessive fat accumulation and a body weight exceeding the standard recommended for a given height, poses a significant health risk. The increasing frequency of non-alcoholic fatty liver disease, owing to the burgeoning obesity crisis, implies that NASH could potentially emerge as the leading cause of serious liver disease in the approaching years, thereby necessitating NASH treatments and associated medications. For example, in March 2024, the World Health Organization (WHO), a UK-based global public health organization, reported that in 2022, nearly 2.5 billion adults, 18 years and older, were identified as overweight, out of which 890 million were diagnosed with obesity. Hence, the surge in obesity cases will propel the expansion of the non-alcoholic steatohepatitis (NASH) market.

How Is the Non-Alcoholic Steatohepatitis (NASH) Market Segmented?

The non-alcoholic steatohepatitis (nash) market covered in this report is segmented –

1) By Type: Solid, Liquid

2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products

3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity

4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider

5) By Application: Oral, Parenteral

Subsegments:

1) By Solid: Tablets, Capsules, Other Solid Dosage Forms

2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=8805&type=smp

Which Regions Are Driving the Next Phase of the Non-Alcoholic Steatohepatitis (NASH) Market Growth?

North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Non-Alcoholic Steatohepatitis (NASH) Industry?

Major firms in the non-alcoholic steatohepatitis (NASH) industry are advancing thyroid hormone receptor-beta (THR-beta) agonists to improve liver metabolism, decrease fat accumulation in the liver and promote better liver function. These agonists are substances that selectively stimulate the thyroid hormone receptor-beta subtype, playing a crucial role in managing metabolism, growth, and development. For example, Rezdiffra (resmetirom), a thyroid hormone receptor-beta agonist was sanctioned as the first treatment for adults with noncirrhotic NASH with moderate to severe liver fibrosis (scarring) by the Food and Drug Administration, a regulatory agency in the US, in March 2024. Rezdiffra, by selectively triggering the THR-beta receptor, helps in managing lipid metabolism, thus reducing intrahepatic triglycerides and overall fat accumulation in the liver.

View the full report here:

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-nash-global-market-report

How Is the Non-Alcoholic Steatohepatitis (NASH) Market Defined and What Are Its Core Parameters?

Non-alcoholic steatohepatitis (NASH) is a severe case of fatty liver disease that is characterized by inflammation of the liver and can proceed to cirrhosis and liver failure.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8805

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What Are the Projected Market Size and Growth Rates for the Non-Alcoholic Steatohepatitis (NASH) Market From 2025 To 2029?#_x000D_

The market size for non-alcoholic steatohepatitis (NASH) has seen a substantial surge in growth in the past few years. Its value is projected to increase from $4.5 billion in 2024 to $6.06 billion in 2025, showcasing a compound annual growth rate (CAGR) of 34.7%. The significant growth experienced during the historical period can be ascribed to factors such as the increasing cases of NASH, escalating obesity crisis, heightened awareness and detection rates, changes in lifestyle and food habits, and advancements in healthcare infrastructure._x000D_

_x000D_

Expectations for the non-alcoholic steatohepatitis (NASH) market show significant expansion in the upcoming years. Notably, it is projected to reach a market size of $18.55 billion by 2029, yielding a compound annual growth rate (CAGR) of 32.3%. This considerable growth can be credited to several factors, including advancements in NASH medication development, the rise in NASH screening initiatives, an increase in healthcare spending, combined research initiatives, and government regulatory support. Key tendencies expected during the forecast period comprise focusing on lifestyle modifications and patient education, fostering collaboration in clinical trials, regulatory progress and pathway designations, as well as the incorporation of artificial intelligence in diagnosis and supervision._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=8805&type=smp_x000D_

_x000D_

#What Are the Core Market Drivers Propelling Growth in the Non-Alcoholic Steatohepatitis (NASH) Industry?#_x000D_

The escalating prevalence of obesity is fuelling the necessity for the non-alcoholic steatohepatitis (NASH) market. Obesity, characterized by abnormal or excessive fat accumulation and a body weight exceeding the standard recommended for a given height, poses a significant health risk. The increasing frequency of non-alcoholic fatty liver disease, owing to the burgeoning obesity crisis, implies that NASH could potentially emerge as the leading cause of serious liver disease in the approaching years, thereby necessitating NASH treatments and associated medications. For example, in March 2024, the World Health Organization (WHO), a UK-based global public health organization, reported that in 2022, nearly 2.5 billion adults, 18 years and older, were identified as overweight, out of which 890 million were diagnosed with obesity. Hence, the surge in obesity cases will propel the expansion of the non-alcoholic steatohepatitis (NASH) market._x000D_

_x000D_

#How Is the Non-Alcoholic Steatohepatitis (NASH) Market Segmented?#_x000D_

The non-alcoholic steatohepatitis (nash) market covered in this report is segmented – _x000D_

_x000D_

1) By Type: Solid, Liquid_x000D_

2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products_x000D_

3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity_x000D_

4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider_x000D_

5) By Application: Oral, Parenteral_x000D_

_x000D_

Subsegments: _x000D_

1) By Solid: Tablets, Capsules, Other Solid Dosage Forms _x000D_

2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms _x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=8805&type=smp_x000D_

_x000D_

#Which Regions Are Driving the Next Phase of the Non-Alcoholic Steatohepatitis (NASH) Market Growth?#_x000D_

North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Key Market Trends and Innovations Are Shaping the Future of the Non-Alcoholic Steatohepatitis (NASH) Industry?#_x000D_

Major firms in the non-alcoholic steatohepatitis (NASH) industry are advancing thyroid hormone receptor-beta (THR-beta) agonists to improve liver metabolism, decrease fat accumulation in the liver and promote better liver function. These agonists are substances that selectively stimulate the thyroid hormone receptor-beta subtype, playing a crucial role in managing metabolism, growth, and development. For example, Rezdiffra (resmetirom), a thyroid hormone receptor-beta agonist was sanctioned as the first treatment for adults with noncirrhotic NASH with moderate to severe liver fibrosis (scarring) by the Food and Drug Administration, a regulatory agency in the US, in March 2024. Rezdiffra, by selectively triggering the THR-beta receptor, helps in managing lipid metabolism, thus reducing intrahepatic triglycerides and overall fat accumulation in the liver._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-nash-global-market-report_x000D_

_x000D_

#How Is the Non-Alcoholic Steatohepatitis (NASH) Market Defined and What Are Its Core Parameters?#_x000D_

Non-alcoholic steatohepatitis (NASH) is a severe case of fatty liver disease that is characterized by inflammation of the liver and can proceed to cirrhosis and liver failure._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8805_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the non-alcoholic steatohepatitis (nash) industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#How Fast Is The Non-Alcoholic Steatohepatitis (NASH) Market Expected to Grow Between 2025 And 2029?#_x000D_

Recently, there has been an exponential surge in the size of the non-alcoholic steatohepatitis (NASH) market. It is predicted to expand from $4.5 billion in 2024 to $6.13 billion in 2025, with a compound annual growth rate (CAGR) of 36.1%. The historical growth pattern can be linked to an increase in NASH prevalence, the obesity crisis, heightened awareness and diagnosis, changes in lifestyle and eating habits, along with the development of the healthcare infrastructure._x000D_

_x000D_

Expectations are high for the non-alcoholic steatohepatitis (NASH) market to experience a surge in size over the coming years. By 2029, the market is projected to reach $19.07 billion, with a compound annual growth rate (CAGR) of 32.8%. This anticipated growth during the forecast period can be linked to various factors such as advancements in NASH medication, a rise in screening initiatives for NASH, increased spending in the health sector, joint research initiatives, as well as support and regulatory measures from the government. Several trends expected to prevail in this period comprise a greater focus on lifestyle modifications and educating patients, amplified partnerships in clinical research, advancements in regulatory and pathway designations, and incorporating artificial intelligence in diagnosis and monitoring._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=8805&type=smp_x000D_

_x000D_

#Which Primay Drivers Are Accelerating Growth in the Non-Alcoholic Steatohepatitis (NASH) Market?#_x000D_

The increase in obesity cases is catapulting the demand for the non-alcoholic steatohepatitis (NASH) market. Obesity is characterized by an abnormal or excessive accumulation of fat, raising health risks and manifesting as body weight exceeding the advisable limit for a person’s height. Non-alcoholic fatty liver disease prevalence has surged, owing to the escalating obesity epidemic, making NASH potentially the most common cause of serious liver disease in the upcoming years. Consequently, this sparks a demand for NASH treatments and related drugs. In confirmation, the World Health Organization (WHO), a UK-based global public health institution, noted in March 2024, that around 2.5 billion adults aged 18 and over were identified as overweight in 2022, with 890 million of them being obese. Therefore, the escalating number of obesity cases is set to spur the growth of the non-alcoholic steatohepatitis (NASH) market._x000D_

_x000D_

#Which Primary Segments of the Non-Alcoholic Steatohepatitis (NASH) Market Are Driving Growth and Industry Transformations?#_x000D_

The non-alcoholic steatohepatitis (NASH) market covered in this report is segmented –_x000D_

_x000D_

1) By Type: Solid, Liquid_x000D_

2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products_x000D_

3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity_x000D_

4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider_x000D_

5) By Application: Oral, Parenteral_x000D_

_x000D_

Subsegments:_x000D_

1) By Solid: Tablets, Capsules, Other Solid Dosage Forms_x000D_

2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=8805&type=smp_x000D_

_x000D_

#Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Non-Alcoholic Steatohepatitis (NASH) Market?# Market?#_x000D_

North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Which Technological Trends Are Reshaping the Non-Alcoholic Steatohepatitis (NASH) Industry Dynamics?#_x000D_

Prominent businesses in the non-alcoholic steatohepatitis (NASH) sector are concentrating their efforts on the production of thyroid hormone receptor-beta (THR-beta) agonists. These compounds are designed to boost liver metabolism, mitigate liver fat buildup, and optimize liver function. The THR-beta agonists are specific compounds that kindle the thyroid hormone receptor-beta subtype, which plays a crucial role in managing metabolism, growth, and development. For instance, Rezdiffra (resmetirom) was given green light by the US’s Food and Drug Administration in March 2024. It’s a THR-beta agonist and is the inaugural treatment for adults afflicted with noncirrhotic NASH presenting moderate to advanced liver scarring (fibrosis). Rezdiffra operates by selectively stimulating the THR-beta receptor, which mediates lipid metabolism, resulting in a decrease in intrahepatic triglycerides and overall liver fat accumulation._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-nash-global-market-report_x000D_

_x000D_

#What Parameters Are Used to Define the Non-Alcoholic Steatohepatitis (NASH) Market?#_x000D_

Non-alcoholic steatohepatitis (NASH) is a severe case of fatty liver disease that is characterized by inflammation of the liver and can proceed to cirrhosis and liver failure._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8805_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Drivers Are Shaping the Growth and Development of theNon-Alcoholic Steatohepatitis (NASH) Market?

The increase in obesity rates is a significant factor propelling the non-alcoholic steatohepatitis (NASH) market. Obesity, defined as abnormal or excessive fat accumulation that carries health risks, as well as weight that exceeds the healthy range for a person’s height, is becoming more prevalent. The incidence of non-alcoholic fatty liver disease is escalating in parallel with the obesity crisis, so it is predicted that in the coming years, NASH may emerge as the leading cause of serious liver disease. This is fuelling the demand for NASH treatments and associated medications. For example, the World Health Organization (WHO), a UK-based global health organization, reported in March 2024 that about 2.5 billion adults of 18 years and above were diagnosed as overweight in 2022, with 890 million of them suffering from obesity. Hence, the escalation in obesity rates is set to spur the growth of the non-alcoholic steatohepatitis (NASH) market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8805&type=smp

#What is the Projected CAGR for the Non-Alcoholic Steatohepatitis (NASH) Market Size from 2025 to 2034?

The market size for non-alcoholic steatohepatitis (NASH) has experienced substantial growth in previous years. The market is expected to elevate from $4.5 billion in 2024 to $6.13 billion in 2025, progressing at a compound annual growth rate (CAGR) of 36.1%. Factors contributing to the growth during the historical period include an increased incidence of NASH and obesity, heightened awareness and diagnoses, changes in lifestyle and diets, and advancements in healthcare infrastructure.

The market for non-alcoholic steatohepatitis (NASH) is projected to experience substantial expansion in the coming years. The market is expected to surge up to $19.07 billion by 2029, advancing at a compound annual growth rate (CAGR) of 32.8%. Factors contributing to this growth in the projected period involve progress in the development of NASH medication, enhanced efforts in NASH screening, escalating healthcare costs, cooperative investigations, and government backing and rules. Key developments during the forecasted period encompass emphasis on lifestyle alterations and patient knowledge-expansion, heightened collaboration in clinical studies and examinations, advancements in regulatory frameworks, allocation of medicinal routes, and implementation of artificial intelligence in diagnosis and monitoring processes.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8805

Which Cutting-Edge Market Trends Are Expected to Drive the Non-Alcoholic Steatohepatitis (NASH) Market’s Growth?

Top corporations in the non-alcoholic steatohepatitis (NASH) market are advancing thyroid hormone receptor-beta (THR-beta) agonists to boost liver metabolism, diminish the build-up of liver fat, and improve liver functionality. These are substances that specifically activate the THR-beta receptor subtype, a significant receptor in the control of metabolism, growth, and development. For instance, in March 2024, the USA’s regulatory body, the Food and Drug Administration, gave approval to Rezdiffra (resmetirom), a THR-beta agonist, as the initial treatment for adults suffering from noncirrhotic NASH with moderate to severe liver scarring, also known as fibrosis. Rezdiffra helps regulate lipid metabolism by specifically activating the THR-beta receptor, resulting in a decrease in intrahepatic triglycerides and overall reduction of liver fat accumulation.

What Are the Leading Market Players Impacting theNon-Alcoholic Steatohepatitis (NASH) Market’s Growth Trend?

Major companies operating in the non-alcoholic steatohepatitis (NASH) market include NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-nash-global-market-report

How Are the Key Segments of the Non-Alcoholic Steatohepatitis (NASH) Market Driving Opportunities and Innovations?

The non-alcoholic steatohepatitis (NASH) market covered in this report is segmented –

1) By Type: Solid, Liquid

2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products

3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity

4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider

5) By Application: Oral, Parenteral

Subsegments:

1) By Solid: Tablets, Capsules, Other Solid Dosage Forms

2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=8805&type=smp

What Regions Are At the Forefront of #What Drivers Are Shaping the Growth and Development of theNon-Alcoholic Steatohepatitis (NASH) Market?# Market Expansion?

North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis (NASH) Market 2025, By The Business Research Company:

Propylene-Petrochemicals Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/propylene-petrochemicals-global-market-report

Petrochemicals Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/petrochemicals-global-market-report

Water-Based Adhesives Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/waterbased-adhesives-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What fueled the previous growth in the non-alcoholic steatohepatitis (nash) market?

In recent times, the market size for non-alcoholic steatohepatitis (NASH) has experienced a significant expansion. The market, which is expected to rise from $4.5 billion in 2024 to $6.13 billion in 2025, projects a compound annual growth rate (CAGR) of 36.1%. Factors attributing to this growth during the historic period include an increase in NASH occurrence, obesity outbreak, a greater understanding and detection, changes in lifestyle and diet regimes, and advancements in healthcare infrastructure.

What will be the non-alcoholic steatohepatitis (nash) market size in the future?

Get your non-alcoholic steatohepatitis (nash) market report here!

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-nash-global-market-report

What main drivers are fueling expansion in the non-alcoholic steatohepatitis (nash) market?

The increasing prevalence of obesity is propelling the need for the non-alcoholic steatohepatitis (NASH) market. Obesity, characterized by unhealthy or excessive fat accumulation and a body weight greater than what is considered appropriate for a person’s height, poses a significant health risk. The widespread occurrence of non-alcoholic fatty liver disease due to the blooming obesity epidemic potentially makes NASH the predominant cause of severe liver disease in the forthcoming years. This, in turn, fuels the necessity for NASH treatments and corresponding medications. As an illustration, in 2024, the World Health Organization (WHO), an international public health organization headquartered in the UK, reported that in 2022 around 2.5 billion adults over the age of 18 were deemed overweight, with 890 million among them being diagnosed with obesity. Hence, the surge in obesity instances will catalyze the expansion of the non-alcoholic steatohepatitis (NASH) market.

What key areas define the segmentation of the global non-alcoholic steatohepatitis (nash) market?

The non-alcoholic steatohepatitis (NASH) market covered in this report is segmented –

1) By Type: Solid, Liquid

2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products

3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity

4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider

5) By Application: Oral, Parenteral

Subsegments:

1) By Solid: Tablets, Capsules, Other Solid Dosage Forms

2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8805&type=smp

Who are the dominant players expanding their reach in the non-alcoholic steatohepatitis (nash) market?

Major companies operating in the non-alcoholic steatohepatitis (NASH) market include NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens.

How are evolving market trends shaping non-alcoholic steatohepatitis (nash) Strategies?

The non-alcoholic steatohepatitis (NASH) market comprises significant players such as NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8805

Which regions are emerging as leaders in the non-alcoholic steatohepatitis (nash) market?

North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Non Alcoholic – Beverages Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/non-alcoholic-beverages-global-market-report

Alcoholic – Beverages Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/alcoholic-beverages-global-market-report

Ethyl Alcohol And Other Basic Organic Chemical Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/ethyl-alcohol-and-other-basic-organic-chemical-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: